Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
New England Journal of Medicine · 29.01.2026 · 394 (5) · 429-441
DOI: 10.1056/nejmoa2512761 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 29.01.2026. Verfasst von Nicholas A Marston und 31 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hypertriglyceridemia, Oligonucleotides, Antisense, Pancreatitis. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: NIDDK NIH HHS, Ionis Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND: Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger RNA, have not been established in this population. METHODS: We conducted two double-blind, randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b). Patients with severe hypertriglyceridemia were assigned in a 1:1:1 ratio to receive olezarsen at a dose of 50 mg, olezarsen at a dose of 80 mg, or placebo monthly for 12 months. The primary outcome was the percent change in the triglyceride level at 6 months, reported as the difference between each olezarsen dose group and the placebo group (placebo-adjusted change). Secondary lipid outcomes included the percent change in the triglyceride level at 12 months and in apolipoprotein C-III, remnant cholesterol, and non-high-density lipoprotein (non-HDL) cholesterol at 6 months and 12 months. Acute pancreatitis events were assessed across both trials. RESULTS: A total of 1061 patients were included in the primary analysis (617 in the CORE-TIMI 72a trial and 444 in the CORE2-TIMI 72b trial). At 6 months, the placebo-adjusted least-squares mean change from baseline in the triglyceride level was -62.9 percentage points in the olezarsen 50-mg group and -72.2 percentage points in the olezarsen 80-mg group in the CORE-TIMI 72a trial and was -49.2 percentage points in the olezarsen 50-mg group and -54.5 percentage points in the olezarsen 80-mg group in the CORE2-TIMI 72b trial (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston.
- Harvard Medical School, Boston.
- Ionis Pharmaceuticals, Carlsbad, CA.
- Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Boston.
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT.
- Veterans Affairs Connecticut Healthcare System, West Haven.
ORCID-Profile: Brian A Bergmark, Erik S G Stroes
Förderung
- NIDDK NIH HHS
- Ionis Pharmaceuticals
Zitieren
APA
Marston, N. A., Bergmark, B. A., Alexander, V. J., Prohaska, T. A., Kang, Y. M., Moura, F. A., Zimerman, A., Waldman, E., Weinland, J., Murphy, S. A., Goodrich, E. L., Zhang, S., Xia, S., Li, D., Goldberg, A. C., Goudev, A., Badimon, L., Kiss, R. G., Vrablik, M., …, & CORE-TIMI 72a and CORE2-TIMI 72b Investigators (2026). Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. New England Journal of Medicine, 394(5), 429-441. https://doi.org/10.1056/nejmoa2512761
Vancouver
Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. New England Journal of Medicine. 2026;394(5):429-441. doi:10.1056/nejmoa2512761
BibTeX
@article{Marston2026,
author = {Marston, Nicholas A and Bergmark, Brian A and Alexander, Veronica J and Prohaska, Thomas A and Kang, Yu Mi and Moura, Filipe A and Zimerman, Andre and Waldman, Elaine and Weinland, Julia and Murphy, Sabina A and Goodrich, Erica L and Zhang, Shuanglu and Xia, Shuting and Li, Dan and Goldberg, Anne C and Goudev, Assen and Badimon, Lina and Kiss, Robert Gabor and Vrablik, Michal and Gaudet, Daniel and Moulin, Philippe and Stroes, Erik S G and Banach, Maciej and Cohen, Hofit and Blom, Dirk and Charng, Min-Ji and Nordestgaard, Børge G and Nicholls, Stephen J and Tsimikas, Sotirios and Giugliano, Robert P and Sabatine, Marc S and CORE-TIMI 72a and CORE2-TIMI 72b Investigators, CORE-TIMI 72a and CORE2-TIMI 72b Investigators},
title = {Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {5},
pages = {429--441},
doi = {10.1056/nejmoa2512761}
}
EUVIMED